The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics. The team is currently investing out of a $987 million venture fund (2022 vintage) and a $830 million public fund (raised in 2021).

Company formation has been a core strategy since 2005. The Frazier team leverages its extensive relationships with pharmaceutical companies and academic institutions to identify and license assets into focused new companies with exceptional management teams.

The Frazier team is active in investing across all rounds of private companies, focusing on opportunities with meaningful clinical read-outs for diseases with unmet medical need.

The Frazier team invests in mezzanine financings and public markets, and takes a long-term view of these investments.

Selected Drug Approvals from our Portfolio

Arcutis Biotherapeutics
Phathom Pharmaceuticals
Phathom Pharmaceuticals
Mirum Pharmaceuticals
AnaptysBio
Silvergate Pharmaceuticals
Nabriva Therapeutics
Ignyta
View More